|Bid||35.64 x 100|
|Ask||72.15 x 100|
|Day's Range||67.41 - 71.17|
|52 Week Range||37.36 - 81.22|
|Beta (3Y Monthly)||3.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||88.00|
Exact Sciences CEO Kevin Conroy recaps his comapany's quarterly results with CNBC's Meg Tirrell, discussing his growth strategy, Exact Sciences' new partnership with Pfizer, and the company's flagship at-home test for colon cancer.
President and CEO of Exact Sciences Corp (NASDAQ:EXAS) Kevin T Conroy sold 163,514 shares of EXAS on 11/12/2018 at an average price of $69 a share.
NEW YORK, NY / ACCESSWIRE / November 13, 2018 / OPKO Health was seeing big gains in Monday’s session on a stellar third quarter report. Shares of Exact Sciences Corp. were plummeting despite any remarkable ...
MADISON, Wis., Nov. 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conference during November and invited investors to participate by webcast. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer.
NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed it established six new positions when it released its third-quarter portfolio. Warning! GuruFocus has detected 7 Warning Signs with COO.
was mentioned during the "Lightning Round" on Jim Cramer's Mad Money program Wednesday night. In the daily bar chart of EXAS, below, we can see a stock chart that looks very hard to trade or even just to buy and hold. The daily On-Balance-Volume (OBV) line generally moves up from a February low to generally confirm the advance.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Oct. 30) Gamida Cell Ltd (NASDAQ: GMDA ) NeoGenomics, Inc. (NASDAQ: ...
NEW YORK, NY / ACCESSWIRE / October 31, 2018 / U.S. markets rebounded on Tuesday as trade tensions eased after President Trump hinted that the U.S. was prepared to negotiate a trade deal with China. During ...
Exact Sciences (EXAS) delivered earnings and revenue surprises of 28.57% and 8.33%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Madison, Wisconsin-based company said it had a loss of 37 cents per share. Losses, adjusted for non-recurring costs, were 30 cents per share. The results beat Wall Street expectations. The average ...
- Demand accelerated from healthcare providers as more than 11,000 ordered their initial Cologuard test during the third quarter, and nearly 132,000 have ordered since the test was launched - Gross margin ...
The recovery in healthcare stocks started in May 2018 but faced some selling pressure in recent weeks as market volatility increased. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) fell by around 4.3% in the last week, and is down slightly on the year.
Investors need to pay close attention to Exact Sciences (EXAS) stock based on the movements in the options market lately.
MADISON, Wis. and SAN DIEGO, Oct. 18, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced the acquisition of Biomatrica, a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. Biomatrica's sample collection tubes, which contain proprietary, sample-stabilizing chemistry, ensure quality preservation of circulating tumor DNA, cells and other biomarkers in biological specimens throughout shipment and storage. Exact Sciences intends to use Biomatrica's proprietary technology to support ongoing and future development of its own blood-based cancer detection tests.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Exact Sciences Corporation (NASDAQ:EXAS), with a market capitalization of US$8.3b, rarely draw their attention from the investing Read More...